Zostavax Vaccine contains Live Attenuated Varicella-Zoster Virus (19400 PFU) and is indicated for the prevention of herpes zoster (shingles) in individuals aged 50 years and older. The vaccine stimulates the immune system to boost varicella-zoster virus-specific cell-mediated immunity, thereby reducing the risk of reactivation of latent virus and subsequent development of shingles and postherpetic neuralgia. Administered as a single subcutaneous injection, Zostavax is contraindicated in individuals with a history of severe allergic reaction to any component of the vaccine, immunocompromised patients, and pregnant women due to the live attenuated nature of the virus. Common adverse reactions include injection site erythema, pain, swelling, and mild systemic symptoms such as headache and fatigue. The vaccine has demonstrated efficacy in reducing the incidence and severity of shingles and associated complications. Prior to administration, patients should be evaluated for immunocompetence and history of varicella infection or vaccination. Zostavax should be stored frozen and protected from light to maintain potency. It is essential to adhere to recommended immunization schedules and consult healthcare professionals for appropriate patient selection and monitoring post-vaccination.